<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01602549</url>
  </required_header>
  <id_info>
    <org_study_id>115816</org_study_id>
    <nct_id>NCT01602549</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastric emptying is the end-result of a complex and carefully regulated series of events
      which follow the ingestion of a meal, each of which is dependent on the other and subject to
      neurohormonal control. Motilin is an endogenous peptide, produced mainly in the duodenum,
      whose physiological action is mediated by motilin receptors located on enteric neurons,
      peripheral terminals of the vagus, and on the smooth muscle of the gut. Motilin and
      non-peptide agonists at motilin receptors increases the gastric emptying rate and therefore
      provide a potential approach to the treatment of a range of clinical conditions in which
      delayed gastric emptying is thought to be part of the physiopathology and may be contributory
      to symptoms. Parkinson's disease (PD) is a progressive neurodegenerative disorder
      characterized by degeneration of nigrostriatal dopaminergic neurones. It affects 1.5% of the
      global population over 65 years of age. Cardinal symptoms comprise bradykinesia, rigidity,
      resting tremors and postural instability. Gastrointestinal dysfunction, including
      gastroparesis, is a frequent feature of PD affecting approximately 90% of patients, and is
      caused by autonomic dysfunction as well as an adverse effect of antiparkinsonian drug
      therapy. The therapeutic mainstay for PD treatment is the neutral amino acid
      L-3,4-dihydroxyphenylalanine (L-DOPA), a dopamine prodrug, as it provides the most rapid and
      effective symptomatic control of motor impairment in PD. The primary determinant of L-DOPA
      bioavailability is gastric emptying (GE); delays in GE slow delivery of L-DOPA to its
      proximal small intestinal absorption sites, increasing the extent of presystemic metabolism,
      and leading to slowed and diminished absorption.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MOT115816 will be conducted as a multi-center, randomized, double-blind, placebo controlled
      study to investigate the ability of the motilin receptor agonist GSK962040 to improve L-DOPA
      pharmacokinetics (PK) by enhancing gastric emptying via motilin receptor agonism. Subjects
      will be randomized to receive 50 mg GSK962040 or placebo in a 2:1 ratio administered orally
      once daily for 7-9 days. The study will consist of a screening/baseline period, a treatment
      period, and a 14-day post treatment safety follow-up visit. During this period participants
      will be asked to attend the study center for 5 visits 3 of which will last approximately 5
      hours. The duration of each patient's participation in the study from screening to follow-up
      visit will be approximately 7-8 weeks. For three of the visits, subjects will visit the
      clinical unit fasted and prior to taking their first morning L-DOPA dose. Volunteers will
      undergo a complete physical (including cardiovascular monitoring (ECG), vital signs, blood
      samples, and medical history), measurement of plasma L-DOPA levels, completion of patient
      diary to capture the amount of awake time (in hours) spent &quot;on&quot; without dyskinesias, &quot;on&quot;
      with troublesome dyskinesias, &quot;on&quot; with non-troublesome dyskinesias, and &quot;off&quot; and gastric
      symptoms, non-motor and motor symptoms assessments (MDS-UPDRS rating scale and &quot;finger taps&quot;)
      and measurement of gastric emptying rate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-normalized Levodopa (L-DOPA) Area Under the Plasma Concentration-time Curve From Zero to 4 Hours AUC(0-4) at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Dose-normalized L-DOPA AUC(0-4) was derived from L-DOPA plasma concentration-time data. AUC is a measure of levodopa exposure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-normalized L-DOPA AUC(0-4) at Day 1 and Day 8</measure>
    <time_frame>Day 1 and Day 8</time_frame>
    <description>Dose-normalized L-DOPA AUC(0-4) was derived from L-DOPA plasma concentration-time data. The adjusted means and ratios (GSK962040 50 mg: Placebo) were estimated using a mixed model fitting treatment, visit, treatment*visit, Baseline L-dopa pharmacokinetic (PK) parameter, and Baseline gastric emptying half-time as fixed effects, and participant as a random effect. AUC is a measure of levodopa exposure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-normalized L-DOPA Maximum Observed Concentration (Cmax) at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Dose-normalized L-DOPA Cmax was derived from L-DOPA plasma concentration-time data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-normalized L-DOPA Cmax at Day 1 and Day 8</measure>
    <time_frame>Day 1 and Day 8</time_frame>
    <description>Dose-normalized L-DOPA Cmax was derived from L-DOPA plasma concentration-time data. The adjusted means and ratios were estimated using a mixed model fitting treatment, visit, treatment*visit, Baseline L-dopa PK parameter, and Baseline gastric emptying half-time as fixed effects, and participant as a random effect.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>L-DOPA Time of Occurrence of Cmax (Tmax) at Baseline, Day 1,and Day 8</measure>
    <time_frame>Baseline, Day 1, and Day 8</time_frame>
    <description>L-DOPA Tmax was derived from L-DOPA plasma concentration-time data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>L-DOPA Terminal Phase Half-life (t1/2) at Baseline, Day 1, and Day 8</measure>
    <time_frame>Baseline, Day 1, and Day 8</time_frame>
    <description>L-DOPA t1/2 was derived from L-DOPA plasma concentration-time data. This endpoint was not assessed because there were insufficient L-DOPA data/profiles to calculate this parameter.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastric Half Emptying Time (GE t1/2) at Baseline (BL), Day 1, and Day 8</measure>
    <time_frame>Baseline, Day 1, and Day 8</time_frame>
    <description>Gastric half emptying time is the time taken for half the contents of the stomach to empty. Gastric emptying was measured using the 13C-oral breath test, which is a tracer method that utilizes 13C, a non-radioactive isotope. Basal breath samples were obtained after an overnight fast or otherwise after 4 hours of fasting following a light meal. On Day 1 and Day 8, participants were then dosed with GSK962040 and additional breath test samples were taken prior to administration of a 13C-labelled test meal. The test meal was consumed approximately 80 minutes later. After consumption of the test meal, breath samples were collected at pre-specified time points over an approximately 4 hour period following the test meal. For the duration of the breath test, no food or drink were allowed. The 13C breath content was determined by isotope ratio mass spectrometry. GE t1/2 was determined by using the cumulative percentage of the administered dose of 13C excreted in breath over 4 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Scores at Baseline, Day 1, and Day 8 (Pre-levodopa Dose)</measure>
    <time_frame>Baseline, Day 1, and Day 8 at pre-levodopa dose</time_frame>
    <description>The MDS-UPDRS is used to assess the status of Parkinson's Disease. It has four parts: Part I (non-motor experiences of daily living), Part II (motor experiences of daily living), Part III (motor examination), and Part IV (motor complications). Each part is made up of several questions, with each question given a score ranging from 0 (normal) to 4 (severe). Part I and Part II consist of 13 items each, and have a score ranging between 0 (normal) and 52 (severe). Part III consists of 33 items, and has a score ranging between 0 (normal) and 132 (severe). Part IV consists of 6 items, and has a score ranging between 0 (normal) and 24 (severe). The total score is the summed score of all four parts and ranges between 0 (normal) and 260 (severe). A higher score indicates more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Scores at Baseline, Day 1, and Day 8 (Pre-dose; 120, 180, and 240 Minutes Post-dose)</measure>
    <time_frame>Baseline, Day 1, and Day 8 at pre-dose and 120, 180, and 240 minutes (min) post-dose (PD); Follow-up visit (up to Day 25)</time_frame>
    <description>The MDS-UPDRS is used to assess the status of Parkinson's Disease. It has four parts: Part I (non-motor experiences of daily living), Part II (motor experiences of daily living), Part III (motor examination), and Part IV (motor complications). Each part is made up of several questions, with each question given a score ranging from 0 (normal) to 4 (severe). Part I and Part II consist of 13 items each, and have a score ranging between 0 (normal) and 52 (severe). Part III consists of 33 items, and has a score ranging between 0 (normal) and 132 (severe). Part IV consists of 6 items, and has a score ranging between 0 (normal) and 24 (severe). The total score is the summed score of all four parts and ranges between 0 (normal) and 260 (severe). A higher score indicates more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period Mean Amount of Hours Spent &quot;ON,&quot; &quot;ON&quot; Without Dyskinesia, &quot;ON&quot; With Non-troublesome Dyskinesia, &quot;ON&quot; With Troublesome Dyskinesia, and &quot;OFF&quot; at Baseline and During the Treatment Period (Days 1-8), Week 1 of Follow-up, and Week 2 of Follow-up</measure>
    <time_frame>Baseline, Days 1-8, Week 1 of Follow-up (Days 6 and 7 of Follow-up; up to Day 16), and Week 2 of Follow-up (Days 13 and 14 of Follow-up; up to Day 23)</time_frame>
    <description>Participants were provided with the &quot;ON/OFF&quot; diary to capture details of the amount of awake time spent on/off of PD symptoms, and were asked to complete the diary daily. Participants checked the box most appropriate for their dominant motor state in the preceding 30-minute period. The catergories included: &quot;ON&quot; (including &quot;ON without dyskinesia&quot; and &quot;ON with non-troublesome dyskinesia&quot;), &quot;ON&quot; with troublesome dyskinesia (TD), and &quot;OFF.&quot; For Baseline, data were collected for 2 days prior to Day 1, and the mean value of the 2 days was used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Times a Participant Could Alternatively Tap Two Counter Keys 30 Centimeters Apart in 1 Minute (Min) at Baseline, Day1, Day 8, and Follow-up</measure>
    <time_frame>Baseline, Day 1, and Day 8 at pre-dose and 0, 30, 60, 90, 120, 180, and 240 minutes post-dose; Follow-up visit (up to Day 25)</time_frame>
    <description>Participants were asked to alternatively tap two keys 30 centimeters apart in 1 minute in two trials with the most affected hand or the dominant hand in symmetric disease. The finger tapping was scored manually by the study staff. The finger-tapping assessment was repeated at eight separate time points (pre-dose, 0 min, 30 min, 60 min, 90 min, 120 min, 180 min, and 240 min post-dose) at each visit (Baseline, Day 1, and Day 8). At each time point, the mean of the two assessments was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily L-DOPA Equivalent Dose at Baseline and on Days 1, 2, 3, 4, 5, 6, 7, 8, and 9</measure>
    <time_frame>Baseline and Days 1, 2, 3, 4, 5, 6, 7, 8, and 9</time_frame>
    <description>Various formulations of L-DOPA were utilized by participants for the treatment of Parkinson's Disease. The total daily L-DOPA equivalent dose was calculated as the sum of all L-DOPA equivalent doses for each L-DOPA-containing drug taken on the same day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Day 1 and Day 8</measure>
    <time_frame>Baseline, Day 1, and Day 8</time_frame>
    <description>Blood pressure measurements were taken at pre-dose and at 0 min (completion of meal) on Day 1 and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Heart Rate at Day 1 and Day 8</measure>
    <time_frame>Baseline, Day 1, and Day 8</time_frame>
    <description>Heart rate measurements were taken at pre-dose and 0 min (completion of meal) on Day 1 and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Indicated Electrocardiogram (ECG) Findings at Day 1 and Day 8</measure>
    <time_frame>Day 1 and Day 8</time_frame>
    <description>ECG measurements were taken at pre-dose and 0 min (completion of meal) on Day 1 and Day 8. The Baseline value was the Day 1 pre-dose value. ECG findings were categorized as normal, abnormal - not clinically significant, and abnormal - clinically significant (CS), based on interpretation by the site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Albumin (ALB) and Total Protein (TP) at Day 4 and Day 8</measure>
    <time_frame>Baseline, Day 4, and Day 8</time_frame>
    <description>ALB and TP measurements were taken at pre-dose on Day 1 (Baseline), Day 4, and Day 8. Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Alkaline Phosphatase (ALP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), and Gamma Glutamyl Transferase (GGT) at Day 4 and Day 8</measure>
    <time_frame>Baseline, Day 4, and Day 8</time_frame>
    <description>ALP, ALT, AST, and GGT measurements were taken at pre-dose on Day 1 (Baseline), Day 4, and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Calcium, Chloride, Carbon Dioxide Content (CO2)/Bicarbonate (BC), Glucose, Potassium, Sodium, Urea/Blood Urea Nitrogen (BUN), and Uric Acid (UA) at Day 4 and Day 8</measure>
    <time_frame>Baseline, Day 4, and Day 8</time_frame>
    <description>Calcium, chloride, CO2/BC, glucose, potassium, sodium, urea/BUN, and UA measurements were taken at pre-dose on Day 1 (Baseline), Day 4, and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Absolute Neutrophil Count (ANC), and Platelet Count (PC) at Day 4 and Day 8</measure>
    <time_frame>Baseline, Day 4, and Day 8</time_frame>
    <description>Basophils, eosinophils, lymphocytes, monocytes, total ANC, and PC measurements were taken at pre-dose on Day 1 (Baseline), Day 4, and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) at Day 4 and Day 8</measure>
    <time_frame>Baseline, Day 4, and Day 8</time_frame>
    <description>Hemoglobin and MCHC measurements were taken at pre-dose on Day 1 (Baseline), Day 4, and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematocrit at Day 4 and Day 8</measure>
    <time_frame>Baseline, Day 4, and Day 8</time_frame>
    <description>Hematocrit measurements were taken at pre-dose on Day 1 (Baseline), Day 4, and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Corpuscle Hemoglobin (MCH) at Day 4 and Day 8</measure>
    <time_frame>Baseline, Day 4, and Day 8</time_frame>
    <description>MCH measurements were taken at pre-dose on Day 1 (Baseline), Day 4, and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Corpuscle Volume (MCV) at Day 4 and Day 8</measure>
    <time_frame>Baseline, Day 4, and Day 8</time_frame>
    <description>MCV measurements were taken at pre-dose on Day 1 (Baseline), Day 4, and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Red Blood Cell Count (RBC) and White Blood Cell Count (WBC) at Day 4 and Day 8</measure>
    <time_frame>Baseline, Day 4, and Day 8</time_frame>
    <description>RBC and WBC measurements were taken at pre-dose on Day 1 (Baseline), Day 4, and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Reticulocytes (RET) at Day 4 and Day 8</measure>
    <time_frame>Baseline, Day 4, and Day 8</time_frame>
    <description>RET measurements were taken at pre-dose on Day 1 (Baseline), Day 4, and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)</measure>
    <time_frame>From the start of study medication until Follow-up (up to Day 25)</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, is a congenital anomaly or birth defect, is associated with liver injury and impaired liver function, or are serious events as per the medical or scientific judgment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GSK962040 Area Under the Plasma Concentration-time Curve From Zero to 5.5 Hours (AUC[0-5.5] and Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC[0-inf]) at Days 1 and 8</measure>
    <time_frame>Day 1 and Day 8</time_frame>
    <description>GSK AUC(0-5.5) and AUC(0-inf) were derived from GSK962040 plasma concentration-time data. Only participants who received GSK962040 50 mg were analyzed. AUC is a measure of levodopa exposure. Data for AUC(0-inf) was analyzed and was only available for Day 1 and not for Day 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GSK962040 Percentage of AUC(0-inf) Obtained by Extrapolation (%AUCex) at Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>GSK962040 %AUCex was derived from GSK962040 plasma concentration-time data. %AUCex is the percentage of the AUC(0-inf) extrapolated from the last PK sample drawn to infinity. This parameter is only reported in conjunction with single-dose AUC(0-inf). Only participants who received GSK962040 50 mg were analyzed. AUC is a measure of levodopa exposure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GSK962040 Cmax at Day1 and Day 8</measure>
    <time_frame>Day 1 and Day 8</time_frame>
    <description>GSK962040 Cmax was derived from GSK962040 plasma concentration-time data. Only participants who received GSK962040 50 mg were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GSK962040 Tmax at Day1 and Day 8</measure>
    <time_frame>Day 1 and Day 8</time_frame>
    <description>GSK962040 tmax was derived from GSK962040 plasma concentration-time data. Only participants who received GSK962040 50 mg were analyzed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Gastroparesis</condition>
  <arm_group>
    <arm_group_label>Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1:2 ratio, placebo, 50 mg administered orally once daily for 7-9 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK962040 (25 mg tablet)</intervention_name>
    <description>25 mg tablet</description>
    <arm_group_label>Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching placebo tablet</description>
    <arm_group_label>Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of idiopathic Parkinson's Disease (according to modified Hoehn &amp; Yahr
             criteria Stages II-IV) and with suboptimal motor control on L-DOPA or L-DOPA
             combination therapy (i.e. wearing off, peak dose dyskinesias, delayed on or no-on
             effects)

          -  Subjects receiving a stable regimen of L-DOPA for at least four weeks prior to
             screening

          -  Patient has gastric half-time of emptying &gt; or = 70 min as determined by 13C oral
             breath test

          -  Between 40 and 80 years of age, inclusive.

          -  Patient has never had a gastrectomy, nor major gastric surgical procedure or any
             evidence of bowel obstruction or strictures within the previous 12 months

          -  Dosage of any concomitant medications has been stable for at least 4 weeks

          -  A female subject is eligible to participate if she is of: Non-childbearing potential
             defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or
             postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a
             blood sample with simultaneous follicle stimulating hormone (FSH) &gt; 40 MlU/ml and
             estradiol &lt; 40 pg/ml (&lt;147 pmol/L) is confirmatory]. Child-bearing potential and is
             abstinent or agrees to use one of the contraception methods listed in Section 8.1 for
             an appropriate period of time (as determined by the product label or investigator)
             prior to the start of dosing to sufficiently minimize the risk of pregnancy at that
             point. Female subjects must agree to use contraception until at least 5 days post-last
             dose.

          -  ALT &lt; 2xULN; alkaline phosphatase and bilirubin â‰¤ 1.5xULN (isolated bilirubin &gt;1.5xULN
             is acceptable if bilirubin is fractionated and direct bilirubin &lt;35%).

          -  Single or Average QTc, QTcB or QTcF&lt; 450 msec; or QTc &lt; 480 msec in subjects with
             Bundle Branch Block.

        Exclusion Criteria:

          -  Late stage advanced subjects with incapacitating peak dose or biphasic dyskinesia ona
             stable L-DOPA regime.

          -  Presence, or history within the previous 3 months, of significant and/or uncontrolled
             psychiatric, neurological (other than Parkinson's disease), gastro-intestinal,
             hematological, endocrinologic, neurological (other than Parkinson's disease),
             cardiovascular disease, active malignancy (other than basal cell cancer) or other
             condition that would in the opinion of the investigator or medical monitor make the
             subject unsuitable for inclusion in this clinical study.

          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody
             result within 3 months of screening

          -  Patient has a gastric pacemaker

          -  Patient is on chronic enteral (e.g., feeding tube) or parenteral feeding

          -  Patient has evidence of severe cardiovascular autonomic neuropathy (e.g. history of
             recurrent syncope in the last 6 months)

          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).

          -  Pregnant females as determined by positive serum or urine hCG test at screening or
             prior to dosing.

          -  Lactating females.

          -  Unable to refrain from consumption of red wine, Seville oranges, grapefruit or
             grapefruit juice from 7 days prior to the first dose of study medication until
             followup.

          -  Use of medications potentially influencing upper gastrointestinal motility or appetite
             within one week of the study (e.g., prokinetic drugs, macrolide antibiotics
             (erythromycin), GLP-1 mimetics)

          -  Unable to refrain from use of prohibited medications listed in Section 9 within the
             restricted timeframe relative to the first dose of study medication.

          -  The patient has participated in a clinical trial and has received an investigational
             product within the following time period prior to the first dosing day in the current
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the
             investigational product (whichever is longer).

          -  History of sensitivity to any of the study medications, or components thereof or a
             history of drug or other allergy that, in the opinion of the investigator or GSK
             Medical Monitor, contraindicates their participation.

          -  Where participation in the study would result in donation of blood or blood products
             in excess of 500 mL within a 56-day time-period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Wuerttemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bochum</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jena</city>
        <state>Thueringen</state>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13088</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <zip>C2B 2PY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE4 5PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Norwich</city>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2012</study_first_submitted>
  <study_first_submitted_qc>May 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2012</study_first_posted>
  <results_first_submitted>December 12, 2016</results_first_submitted>
  <results_first_submitted_qc>December 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 6, 2017</results_first_posted>
  <last_update_submitted>December 12, 2016</last_update_submitted>
  <last_update_submitted_qc>December 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The study consisted of a Screening/Baseline Period, a Treatment Period, and a 14-day post-treatment safety Follow-up Visit. Participants were randomized to receive GSK962040 50 milligrams or placebo in a 2:1 ratio; one participant was randomized to receive GSK962040 125 mg.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
        </group>
        <group group_id="P2">
          <title>GSK962040 Total</title>
          <description>Participants received GSK962040 50 milligrams (mg) (except for one participant who received GSK962040 125 mg) administered orally once daily for 7 to 9 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The GSK962040 data include 37 subjects who received the 50-mg dose and 1 subject who received the 125-mg dose&quot; in the baseline description.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
        </group>
        <group group_id="B2">
          <title>GSK962040 Total</title>
          <description>Participants received GSK962040 50 milligrams (mg) (except for one participant who received GSK962040 125 mg) administered orally once daily for 7 to 9 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="57"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.7" spread="8.04"/>
                    <measurement group_id="B2" value="67.4" spread="7.97"/>
                    <measurement group_id="B3" value="67.1" spread="7.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White - White/Caucasian/European Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Dose-normalized Levodopa (L-DOPA) Area Under the Plasma Concentration-time Curve From Zero to 4 Hours AUC(0-4) at Baseline</title>
        <description>Dose-normalized L-DOPA AUC(0-4) was derived from L-DOPA plasma concentration-time data. AUC is a measure of levodopa exposure.</description>
        <time_frame>Baseline</time_frame>
        <population>Pharmacodynamic (PD)/Efficacy Population: participants receiving &gt;=1 dose placebo/GSK962040 50 mg. Only those participants available at the specified time point were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 milligrams (mg) administered orally once daily for 7 to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-normalized Levodopa (L-DOPA) Area Under the Plasma Concentration-time Curve From Zero to 4 Hours AUC(0-4) at Baseline</title>
          <description>Dose-normalized L-DOPA AUC(0-4) was derived from L-DOPA plasma concentration-time data. AUC is a measure of levodopa exposure.</description>
          <population>Pharmacodynamic (PD)/Efficacy Population: participants receiving &gt;=1 dose placebo/GSK962040 50 mg. Only those participants available at the specified time point were analyzed.</population>
          <units>Nanograms*hour/milliliter/milligram</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.13" spread="37.5"/>
                    <measurement group_id="O2" value="24.81" spread="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-normalized L-DOPA AUC(0-4) at Day 1 and Day 8</title>
        <description>Dose-normalized L-DOPA AUC(0-4) was derived from L-DOPA plasma concentration-time data. The adjusted means and ratios (GSK962040 50 mg: Placebo) were estimated using a mixed model fitting treatment, visit, treatment*visit, Baseline L-dopa pharmacokinetic (PK) parameter, and Baseline gastric emptying half-time as fixed effects, and participant as a random effect. AUC is a measure of levodopa exposure</description>
        <time_frame>Day 1 and Day 8</time_frame>
        <population>PD/Efficacy Population. Participants with available data (n=X, X in category titles) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 milligrams (mg) administered orally once daily for 7 to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-normalized L-DOPA AUC(0-4) at Day 1 and Day 8</title>
          <description>Dose-normalized L-DOPA AUC(0-4) was derived from L-DOPA plasma concentration-time data. The adjusted means and ratios (GSK962040 50 mg: Placebo) were estimated using a mixed model fitting treatment, visit, treatment*visit, Baseline L-dopa pharmacokinetic (PK) parameter, and Baseline gastric emptying half-time as fixed effects, and participant as a random effect. AUC is a measure of levodopa exposure</description>
          <population>PD/Efficacy Population. Participants with available data (n=X, X in category titles) were analyzed.</population>
          <units>Nanograms*hour/milliliter/milligram</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, n=17, 31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6" spread="0.058"/>
                    <measurement group_id="O2" value="25.7" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, n=17, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1" spread="0.058"/>
                    <measurement group_id="O2" value="24.1" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GSK962040 50 mg : Placebo Day 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means</param_type>
            <param_value>0.965</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.831</ci_lower_limit>
            <ci_upper_limit>1.120</ci_upper_limit>
            <estimate_desc>Day 1: The adjusted means (AMs) and ratios were estimated using a mixed model (MM) fitting treatment, visit, treatment*visit, Baseline L-dopa PK parameter and Baseline gastric emptying half time as fixed effects, and participant as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GSK962040 50 mg : Placebo Day 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means</param_type>
            <param_value>0.886</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.763</ci_lower_limit>
            <ci_upper_limit>1.029</ci_upper_limit>
            <estimate_desc>Day 8: The AMs and ratios were estimated using a mixed model fitting treatment, visit, treatment*visit, Baseline L-dopa PK parameter and Baseline gastric emptying half time as fixed effects, and participant as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 8: Day 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means</param_type>
            <param_value>0.937</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.850</ci_lower_limit>
            <ci_upper_limit>1.033</ci_upper_limit>
            <estimate_desc>Day 8:Day 1: The AMs and ratios were estimated using a mixed model fitting treatment, visit, treatment*visit, Baseline L-dopa PK parameter and Baseline gastric emptying half time as fixed effects, and participant as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Day 8:Day 1 Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means</param_type>
            <param_value>1.020</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.890</ci_lower_limit>
            <ci_upper_limit>1.170</ci_upper_limit>
            <estimate_desc>Day 8:Day 1: The AMs and ratios were estimated using a mixed model fitting treatment, visit, treatment*visit, Baseline L-dopa PK parameter and Baseline gastric emptying half time as fixed effects, and participant as a random effect.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-normalized L-DOPA Maximum Observed Concentration (Cmax) at Baseline</title>
        <description>Dose-normalized L-DOPA Cmax was derived from L-DOPA plasma concentration-time data.</description>
        <time_frame>Baseline</time_frame>
        <population>PD/Efficacy Population. Only those participants available at the specified time point were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 milligrams (mg) administered orally once daily for 7 to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-normalized L-DOPA Maximum Observed Concentration (Cmax) at Baseline</title>
          <description>Dose-normalized L-DOPA Cmax was derived from L-DOPA plasma concentration-time data.</description>
          <population>PD/Efficacy Population. Only those participants available at the specified time point were analyzed.</population>
          <units>Nanograms/milliliter/milligram</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.77" spread="28.0"/>
                    <measurement group_id="O2" value="12.89" spread="42.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-normalized L-DOPA Cmax at Day 1 and Day 8</title>
        <description>Dose-normalized L-DOPA Cmax was derived from L-DOPA plasma concentration-time data. The adjusted means and ratios were estimated using a mixed model fitting treatment, visit, treatment*visit, Baseline L-dopa PK parameter, and Baseline gastric emptying half-time as fixed effects, and participant as a random effect.</description>
        <time_frame>Day 1 and Day 8</time_frame>
        <population>PD/Efficacy Population. Participants with available data (n=X, X in category titles) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 milligrams (mg) administered orally once daily for 7 to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-normalized L-DOPA Cmax at Day 1 and Day 8</title>
          <description>Dose-normalized L-DOPA Cmax was derived from L-DOPA plasma concentration-time data. The adjusted means and ratios were estimated using a mixed model fitting treatment, visit, treatment*visit, Baseline L-dopa PK parameter, and Baseline gastric emptying half-time as fixed effects, and participant as a random effect.</description>
          <population>PD/Efficacy Population. Participants with available data (n=X, X in category titles) were analyzed.</population>
          <units>Nanograms/milliliter/milligram</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, n=18, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" spread="0.081"/>
                    <measurement group_id="O2" value="11.6" spread="0.065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, n=17, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="0.083"/>
                    <measurement group_id="O2" value="11.8" spread="0.065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GSK962040 50 mg Vs Placebo Day 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means</param_type>
            <param_value>0.864</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.702</ci_lower_limit>
            <ci_upper_limit>1.064</ci_upper_limit>
            <estimate_desc>Day 1: The AMs and ratios were estimated using a mixed model fitting treatment, visit, treatment*visit, Baseline L-dopa PK parameter and Baseline gastric emptying half time as fixed effects, and participant as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GSK962040 50 mg Vs Placebo Day 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means</param_type>
            <param_value>1.018</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.824</ci_lower_limit>
            <ci_upper_limit>1.257</ci_upper_limit>
            <estimate_desc>Day 8: The AMs and ratios were estimated using a mixed model fitting treatment, visit, treatment*visit, Baseline L-dopa PK parameter and Baseline gastric emptying half time as fixed effects, and participant as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 8 VS Day 1 GSK962040 50 mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means</param_type>
            <param_value>1.018</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.889</ci_lower_limit>
            <ci_upper_limit>1.166</ci_upper_limit>
            <estimate_desc>Day 8:Day 1: The AMs and ratios were estimated using a mixed model fitting treatment, visit, treatment*visit, Baseline L-dopa PK parameter and Baseline gastric emptying half time as fixed effects, and participant as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Day 8 Vs Day 1 Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means</param_type>
            <param_value>0.865</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.709</ci_lower_limit>
            <ci_upper_limit>1.055</ci_upper_limit>
            <estimate_desc>Day 8:Day 1: The AMs and ratios were estimated using a mixed model fitting treatment, visit, treatment*visit, Baseline L-dopa PK parameter and Baseline gastric emptying half time as fixed effects, and participant as a random effect.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>L-DOPA Time of Occurrence of Cmax (Tmax) at Baseline, Day 1,and Day 8</title>
        <description>L-DOPA Tmax was derived from L-DOPA plasma concentration-time data.</description>
        <time_frame>Baseline, Day 1, and Day 8</time_frame>
        <population>PD/Efficacy Population. Participants with available data (n=X, X in category titles) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 milligrams (mg) administered orally once daily for 7 to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>L-DOPA Time of Occurrence of Cmax (Tmax) at Baseline, Day 1,and Day 8</title>
          <description>L-DOPA Tmax was derived from L-DOPA plasma concentration-time data.</description>
          <population>PD/Efficacy Population. Participants with available data (n=X, X in category titles) were analyzed.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, n=17, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="0.3" upper_limit="3.6"/>
                    <measurement group_id="O2" value="2.00" lower_limit="0.3" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, n=18, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" lower_limit="0.5" upper_limit="3.4"/>
                    <measurement group_id="O2" value="1.50" lower_limit="0.3" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, n=17, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="0.5" upper_limit="3.5"/>
                    <measurement group_id="O2" value="1.55" lower_limit="0.3" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.157</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.186</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>L-DOPA Terminal Phase Half-life (t1/2) at Baseline, Day 1, and Day 8</title>
        <description>L-DOPA t1/2 was derived from L-DOPA plasma concentration-time data. This endpoint was not assessed because there were insufficient L-DOPA data/profiles to calculate this parameter.</description>
        <time_frame>Baseline, Day 1, and Day 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 milligrams (mg) administered orally once daily for 7 to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>L-DOPA Terminal Phase Half-life (t1/2) at Baseline, Day 1, and Day 8</title>
          <description>L-DOPA t1/2 was derived from L-DOPA plasma concentration-time data. This endpoint was not assessed because there were insufficient L-DOPA data/profiles to calculate this parameter.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gastric Half Emptying Time (GE t1/2) at Baseline (BL), Day 1, and Day 8</title>
        <description>Gastric half emptying time is the time taken for half the contents of the stomach to empty. Gastric emptying was measured using the 13C-oral breath test, which is a tracer method that utilizes 13C, a non-radioactive isotope. Basal breath samples were obtained after an overnight fast or otherwise after 4 hours of fasting following a light meal. On Day 1 and Day 8, participants were then dosed with GSK962040 and additional breath test samples were taken prior to administration of a 13C-labelled test meal. The test meal was consumed approximately 80 minutes later. After consumption of the test meal, breath samples were collected at pre-specified time points over an approximately 4 hour period following the test meal. For the duration of the breath test, no food or drink were allowed. The 13C breath content was determined by isotope ratio mass spectrometry. GE t1/2 was determined by using the cumulative percentage of the administered dose of 13C excreted in breath over 4 hours.</description>
        <time_frame>Baseline, Day 1, and Day 8</time_frame>
        <population>PD/Efficacy Population. Participants with available data (n=X, X in category titles) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 milligrams (mg) administered orally once daily for 7 to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Gastric Half Emptying Time (GE t1/2) at Baseline (BL), Day 1, and Day 8</title>
          <description>Gastric half emptying time is the time taken for half the contents of the stomach to empty. Gastric emptying was measured using the 13C-oral breath test, which is a tracer method that utilizes 13C, a non-radioactive isotope. Basal breath samples were obtained after an overnight fast or otherwise after 4 hours of fasting following a light meal. On Day 1 and Day 8, participants were then dosed with GSK962040 and additional breath test samples were taken prior to administration of a 13C-labelled test meal. The test meal was consumed approximately 80 minutes later. After consumption of the test meal, breath samples were collected at pre-specified time points over an approximately 4 hour period following the test meal. For the duration of the breath test, no food or drink were allowed. The 13C breath content was determined by isotope ratio mass spectrometry. GE t1/2 was determined by using the cumulative percentage of the administered dose of 13C excreted in breath over 4 hours.</description>
          <population>PD/Efficacy Population. Participants with available data (n=X, X in category titles) were analyzed.</population>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, n=19, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" spread="21.26"/>
                    <measurement group_id="O2" value="96.9" spread="21.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, n=19, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5" spread="15.81"/>
                    <measurement group_id="O2" value="91.9" spread="21.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, n=17, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7" spread="25.03"/>
                    <measurement group_id="O2" value="90.6" spread="26.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GSK962040 50 mg Vs Placebo Day 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>-4.239</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.015</ci_lower_limit>
            <ci_upper_limit>7.537</ci_upper_limit>
            <estimate_desc>Day 1: The AMs and differences (GSK962040 minus Placebo) were estimated using a mixed model fitting treatment, visit, treatment*visit, and Baseline gastric half emptying time as fixed effects, and participant as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GSK962040 50 mg Vs Placebo Day 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>-5.327</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.567</ci_lower_limit>
            <ci_upper_limit>6.914</ci_upper_limit>
            <estimate_desc>Day 8: The AMs and differences (GSK962040 minus Placebo) were estimated using a mixed model fitting treatment, visit, treatment*visit, and Baseline gastric half emptying time as fixed effects, and participant as a random effect.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Scores at Baseline, Day 1, and Day 8 (Pre-levodopa Dose)</title>
        <description>The MDS-UPDRS is used to assess the status of Parkinson's Disease. It has four parts: Part I (non-motor experiences of daily living), Part II (motor experiences of daily living), Part III (motor examination), and Part IV (motor complications). Each part is made up of several questions, with each question given a score ranging from 0 (normal) to 4 (severe). Part I and Part II consist of 13 items each, and have a score ranging between 0 (normal) and 52 (severe). Part III consists of 33 items, and has a score ranging between 0 (normal) and 132 (severe). Part IV consists of 6 items, and has a score ranging between 0 (normal) and 24 (severe). The total score is the summed score of all four parts and ranges between 0 (normal) and 260 (severe). A higher score indicates more severe symptoms.</description>
        <time_frame>Baseline, Day 1, and Day 8 at pre-levodopa dose</time_frame>
        <population>PD/Efficacy Population. Participants with available data (n=X, X in category titles) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 milligrams (mg) administered orally once daily for 7 to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Scores at Baseline, Day 1, and Day 8 (Pre-levodopa Dose)</title>
          <description>The MDS-UPDRS is used to assess the status of Parkinson's Disease. It has four parts: Part I (non-motor experiences of daily living), Part II (motor experiences of daily living), Part III (motor examination), and Part IV (motor complications). Each part is made up of several questions, with each question given a score ranging from 0 (normal) to 4 (severe). Part I and Part II consist of 13 items each, and have a score ranging between 0 (normal) and 52 (severe). Part III consists of 33 items, and has a score ranging between 0 (normal) and 132 (severe). Part IV consists of 6 items, and has a score ranging between 0 (normal) and 24 (severe). The total score is the summed score of all four parts and ranges between 0 (normal) and 260 (severe). A higher score indicates more severe symptoms.</description>
          <population>PD/Efficacy Population. Participants with available data (n=X, X in category titles) were analyzed.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Part I: Baseline, n=19, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="4.56"/>
                    <measurement group_id="O2" value="10.1" spread="6.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part I: Day 1, n=19, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="4.98"/>
                    <measurement group_id="O2" value="8.6" spread="5.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part I: Day 8, n=18, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="5.25"/>
                    <measurement group_id="O2" value="7.1" spread="4.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part II: Baseline, n=19, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" spread="7.09"/>
                    <measurement group_id="O2" value="12.5" spread="6.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part II: Day 1, n=19, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" spread="9.09"/>
                    <measurement group_id="O2" value="11.5" spread="6.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part II: Day 8, n=18, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" spread="9.29"/>
                    <measurement group_id="O2" value="10.3" spread="6.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part III: Baseline, n=19, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.2" spread="14.63"/>
                    <measurement group_id="O2" value="38.0" spread="18.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part III: Day 1, n=19, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4" spread="17.56"/>
                    <measurement group_id="O2" value="34.9" spread="17.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part III: Day 8, n=18, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2" spread="19.25"/>
                    <measurement group_id="O2" value="34.0" spread="17.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part IV: Baseline, n=19, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="2.70"/>
                    <measurement group_id="O2" value="5.3" spread="3.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part IV: Day 1, n=19, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="3.07"/>
                    <measurement group_id="O2" value="5.2" spread="3.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part IV: Day 8, n=18, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="3.79"/>
                    <measurement group_id="O2" value="4.5" spread="3.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total: Baseline, n=19, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.7" spread="23.53"/>
                    <measurement group_id="O2" value="65.8" spread="27.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total: Day 1, n=19, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.5" spread="29.01"/>
                    <measurement group_id="O2" value="60.2" spread="25.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total: Day 8, n=18, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.2" spread="34.27"/>
                    <measurement group_id="O2" value="55.9" spread="25.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part I-GSK962040 50 mg Vs Placebo Day 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>-2.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.90</ci_lower_limit>
            <ci_upper_limit>-0.41</ci_upper_limit>
            <estimate_desc>Day 1; Part I: The AMs and differences (GSK 962040 minus Placebo) were estimated using a mixed model fitting treatment, visit, treatment*visit interaction, and Baseline MDS-UPDR score as fixed effects, and participant as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part I-GSK962040 50 mg Vs Placebo Day 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>-3.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.41</ci_lower_limit>
            <ci_upper_limit>-1.85</ci_upper_limit>
            <estimate_desc>Day 8; Part I: The AMs and differences (GSK 962040 minus Placebo) were estimated using a mixed model fitting treatment, visit, treatment*visit interaction, and Baseline MDS-UPDR score as fixed effects, and participant as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part II- GSK962040 50 mg Vs Placebo Day 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>-2.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.65</ci_lower_limit>
            <ci_upper_limit>0.07</ci_upper_limit>
            <estimate_desc>Day 1; Part II: The AMs and differences (GSK 962040 minus Placebo) were estimated using a mixed model fitting treatment, visit, treatment*visit interaction, and Baseline MDS-UPDR score as fixed effects, and participant as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part II- GSK962040 50 mg Vs Placebo Day 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>-2.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.85</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
            <estimate_desc>Day 8; Part II: The AMs and differences (GSK 962040 minus Placebo) were estimated using a mixed model fitting treatment, visit, treatment*visit interaction, and Baseline MDS-UPDR score as fixed effects, and participant as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part III -GSK962040 50 mg Vs Placebo Day 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>-5.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.28</ci_lower_limit>
            <ci_upper_limit>-0.49</ci_upper_limit>
            <estimate_desc>Day 8; Part III: The AMs and differences (GSK 962040 minus Placebo) were estimated using a mixed model fitting treatment, visit, treatment*visit interaction, and Baseline MDS-UPDR score as fixed effects, and participant as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part IV-GSK962040 50 mg Vs Placebo Day 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>-0.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.65</ci_lower_limit>
            <ci_upper_limit>0.54</ci_upper_limit>
            <estimate_desc>Day 1; Part IV: The AMs and differences (GSK 962040 minus Placebo) were estimated using a mixed model fitting treatment, visit, treatment*visit interaction, and Baseline MDS-UPDR score as fixed effects, and participant as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part IV-GSK962040 50 mg Vs Placebo Day 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>-0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.02</ci_lower_limit>
            <ci_upper_limit>0.22</ci_upper_limit>
            <estimate_desc>Day 8; Part IV: The AMs and differences (GSK 962040 minus Placebo) were estimated using a mixed model fitting treatment, visit, treatment*visit interaction, and Baseline MDS-UPDR score as fixed effects, and participant as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total- GSK962040 50 mg Vs Placebo Day 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>-6.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.77</ci_lower_limit>
            <ci_upper_limit>0.39</ci_upper_limit>
            <estimate_desc>Day 1; Total: The AMs and differences (GSK 962040 minus Placebo) were estimated using a mixed model fitting treatment, visit, treatment*visit interaction, and Baseline MDS-UPDR score as fixed effects, and participant as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total- GSK962040 50 mg Vs Placebo Day 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>-12.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.67</ci_lower_limit>
            <ci_upper_limit>-5.29</ci_upper_limit>
            <estimate_desc>Day 8; Total: The AMs and differences (GSK 962040 minus Placebo) were estimated using a mixed model fitting treatment, visit, treatment*visit interaction, and Baseline MDS-UPDR score as fixed effects, and participant as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part III- GSK962040 50 mg Vs Placebo Day 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>-1.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.53</ci_lower_limit>
            <ci_upper_limit>3.13</ci_upper_limit>
            <estimate_desc>Day 1; Part III: The AMs and differences (GSK 962040 minus Placebo) were estimated using a mixed model fitting treatment, visit, treatment*visit interaction, and Baseline MDS-UPDR score as fixed effects, and participant as a random effect.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Scores at Baseline, Day 1, and Day 8 (Pre-dose; 120, 180, and 240 Minutes Post-dose)</title>
        <description>The MDS-UPDRS is used to assess the status of Parkinson's Disease. It has four parts: Part I (non-motor experiences of daily living), Part II (motor experiences of daily living), Part III (motor examination), and Part IV (motor complications). Each part is made up of several questions, with each question given a score ranging from 0 (normal) to 4 (severe). Part I and Part II consist of 13 items each, and have a score ranging between 0 (normal) and 52 (severe). Part III consists of 33 items, and has a score ranging between 0 (normal) and 132 (severe). Part IV consists of 6 items, and has a score ranging between 0 (normal) and 24 (severe). The total score is the summed score of all four parts and ranges between 0 (normal) and 260 (severe). A higher score indicates more severe symptoms.</description>
        <time_frame>Baseline, Day 1, and Day 8 at pre-dose and 120, 180, and 240 minutes (min) post-dose (PD); Follow-up visit (up to Day 25)</time_frame>
        <population>PD/Efficacy Population. Participants with available data (n=X, X in category titles) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 milligrams (mg) administered orally once daily for 7 to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Scores at Baseline, Day 1, and Day 8 (Pre-dose; 120, 180, and 240 Minutes Post-dose)</title>
          <description>The MDS-UPDRS is used to assess the status of Parkinson's Disease. It has four parts: Part I (non-motor experiences of daily living), Part II (motor experiences of daily living), Part III (motor examination), and Part IV (motor complications). Each part is made up of several questions, with each question given a score ranging from 0 (normal) to 4 (severe). Part I and Part II consist of 13 items each, and have a score ranging between 0 (normal) and 52 (severe). Part III consists of 33 items, and has a score ranging between 0 (normal) and 132 (severe). Part IV consists of 6 items, and has a score ranging between 0 (normal) and 24 (severe). The total score is the summed score of all four parts and ranges between 0 (normal) and 260 (severe). A higher score indicates more severe symptoms.</description>
          <population>PD/Efficacy Population. Participants with available data (n=X, X in category titles) were analyzed.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, pre-dose, n=19, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.2" spread="14.63"/>
                    <measurement group_id="O2" value="38.0" spread="18.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, 120 minutes post-dose, n=19, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.1" spread="16.61"/>
                    <measurement group_id="O2" value="27.7" spread="16.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, 180 minutes post-dose, n=19, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.3" spread="14.55"/>
                    <measurement group_id="O2" value="27.5" spread="14.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, 240 minutes post-dose, n=19, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.6" spread="16.27"/>
                    <measurement group_id="O2" value="29.2" spread="16.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, pre-dose, n=19, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4" spread="17.56"/>
                    <measurement group_id="O2" value="34.9" spread="17.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,120 minutes post-dose, n=19, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3" spread="15.01"/>
                    <measurement group_id="O2" value="26.2" spread="16.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 180 minutes post-dose, n=19, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0" spread="17.10"/>
                    <measurement group_id="O2" value="25.5" spread="18.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 240 minutes post-dose, n=19, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7" spread="20.50"/>
                    <measurement group_id="O2" value="27.2" spread="17.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, pre-dose n=18, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2" spread="19.25"/>
                    <measurement group_id="O2" value="34.0" spread="17.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, 120 minutes post-dose, n=18, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3" spread="14.90"/>
                    <measurement group_id="O2" value="24.2" spread="14.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, 180 minutes post-dose, n=18, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" spread="16.17"/>
                    <measurement group_id="O2" value="25.1" spread="14.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, 240 minutes post-dose, n=18, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.1" spread="20.19"/>
                    <measurement group_id="O2" value="25.4" spread="15.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up, n=19, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.3" spread="13.45"/>
                    <measurement group_id="O2" value="24.9" spread="11.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pre dose: GSK962040 50 mg Vs Placebo Day 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>-3.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.07</ci_lower_limit>
            <ci_upper_limit>2.78</ci_upper_limit>
            <estimate_desc>Day 1; Pre-dose: The AMs and differences (GSK962040 minus Placebo) were estimated using a mixed model fitting treatment, visit, treatment*visit*time point interaction, and Baseline UPDRS-3 score as fixed effects, and participant as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>120 min PD: GSK962040 50 mg Vs Placebo Day 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>-3.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.11</ci_lower_limit>
            <ci_upper_limit>2.75</ci_upper_limit>
            <estimate_desc>Day 1; 120 min PD: The AMs and differences (GSK962040 minus Placebo) were estimated using a mixed model fitting treatment, visit, treatment*visit*time point interaction, and Baseline UPDRS-3 score as fixed effects, and participant as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>180 min PD: GSK962040 50 mg Vs Placebo Day 1:</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>-3.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.59</ci_lower_limit>
            <ci_upper_limit>2.27</ci_upper_limit>
            <estimate_desc>Day 1; 180 min PD: The AMs and differences (GSK962040 minus Placebo) were estimated using a mixed model fitting treatment, visit, treatment*visit*time point interaction, and Baseline UPDRS-3 score as fixed effects, and participant as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>240 min PD: GSK962040 50 mg Vs Placebo Day 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>-4.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.07</ci_lower_limit>
            <ci_upper_limit>1.76</ci_upper_limit>
            <estimate_desc>Day 1; 240 min PD: The AMs and differences (GSK962040 minus Placebo) were estimated using a mixed model fitting treatment, visit, treatment*visit*time point interaction, and Baseline UPDRS-3 score as fixed effects, and participant as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pre dose: GSK962040 50 mg Vs Placebo Day 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>-6.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.79</ci_lower_limit>
            <ci_upper_limit>-0.81</ci_upper_limit>
            <estimate_desc>Day 8; Pre-dose: The AMs and differences (GSK962040 minus Placebo) were estimated using a mixed model fitting treatment, visit, treatment*visit*time point interaction, and Baseline UPDRS-3 score as fixed effects, and participant as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>120 min PD: GSK962040 50 mg Vs Placebo Day 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>-3.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.96</ci_lower_limit>
            <ci_upper_limit>2.03</ci_upper_limit>
            <estimate_desc>Day 8; 120 min PD: The AMs and differences (GSK962040 minus Placebo) were estimated using a mixed model fitting treatment, visit, treatment*visit*time point interaction, and Baseline UPDRS-3 score as fixed effects, and participant as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>180 min PD: GSK962040 50 mg Vs Placebo Day 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>-5.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.29</ci_lower_limit>
            <ci_upper_limit>0.71</ci_upper_limit>
            <estimate_desc>Day 8; 180 min PD: The AMs and differences (GSK962040 minus Placebo) were estimated using a mixed model fitting treatment, visit, treatment*visit*time point interaction, and Baseline UPDRS-3 score as fixed effects, and participant as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>240 min PD: GSK962040 50 mg Vs Placebo Day 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>-8.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.88</ci_lower_limit>
            <ci_upper_limit>-2.91</ci_upper_limit>
            <estimate_desc>Day 8; 240 min PD: The AMs and differences (GSK962040 minus Placebo) were estimated using a mixed model fitting treatment, visit, treatment*visit*time point interaction, and Baseline UPDRS-3 score as fixed effects, and participant as a random effect.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period Mean Amount of Hours Spent â€œON,â€ â€œONâ€ Without Dyskinesia, &quot;ON&quot; With Non-troublesome Dyskinesia, &quot;ON&quot; With Troublesome Dyskinesia, and â€œOFFâ€ at Baseline and During the Treatment Period (Days 1-8), Week 1 of Follow-up, and Week 2 of Follow-up</title>
        <description>Participants were provided with the &quot;ON/OFF&quot; diary to capture details of the amount of awake time spent on/off of PD symptoms, and were asked to complete the diary daily. Participants checked the box most appropriate for their dominant motor state in the preceding 30-minute period. The catergories included: &quot;ON&quot; (including â€œON without dyskinesiaâ€ and â€œON with non-troublesome dyskinesia&quot;), &quot;ON&quot; with troublesome dyskinesia (TD), and &quot;OFF.&quot; For Baseline, data were collected for 2 days prior to Day 1, and the mean value of the 2 days was used.</description>
        <time_frame>Baseline, Days 1-8, Week 1 of Follow-up (Days 6 and 7 of Follow-up; up to Day 16), and Week 2 of Follow-up (Days 13 and 14 of Follow-up; up to Day 23)</time_frame>
        <population>PD/Efficacy Population. Participants with available data (n=X, X in category titles) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 milligrams (mg) administered orally once daily for 7 to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Period Mean Amount of Hours Spent â€œON,â€ â€œONâ€ Without Dyskinesia, &quot;ON&quot; With Non-troublesome Dyskinesia, &quot;ON&quot; With Troublesome Dyskinesia, and â€œOFFâ€ at Baseline and During the Treatment Period (Days 1-8), Week 1 of Follow-up, and Week 2 of Follow-up</title>
          <description>Participants were provided with the &quot;ON/OFF&quot; diary to capture details of the amount of awake time spent on/off of PD symptoms, and were asked to complete the diary daily. Participants checked the box most appropriate for their dominant motor state in the preceding 30-minute period. The catergories included: &quot;ON&quot; (including â€œON without dyskinesiaâ€ and â€œON with non-troublesome dyskinesia&quot;), &quot;ON&quot; with troublesome dyskinesia (TD), and &quot;OFF.&quot; For Baseline, data were collected for 2 days prior to Day 1, and the mean value of the 2 days was used.</description>
          <population>PD/Efficacy Population. Participants with available data (n=X, X in category titles) were analyzed.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: &quot;ON,&quot; n=18, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.21" spread="3.602"/>
                    <measurement group_id="O2" value="11.31" spread="3.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: &quot;ON&quot; without dyskinesia, n=18, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.11" spread="4.069"/>
                    <measurement group_id="O2" value="9.65" spread="3.787"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: &quot;ON&quot; with non-TD, n=18, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" spread="1.787"/>
                    <measurement group_id="O2" value="1.66" spread="2.956"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: &quot;ON&quot; with TD, n=18, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="1.240"/>
                    <measurement group_id="O2" value="0.40" spread="1.292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: &quot;OFF,&quot; n=18, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.92" spread="3.417"/>
                    <measurement group_id="O2" value="4.23" spread="2.484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment period: &quot;ON,&quot; n=18, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.61" spread="3.927"/>
                    <measurement group_id="O2" value="12.44" spread="3.375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment period: &quot;ON&quot; without dyskinesia, n=18,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.82" spread="4.042"/>
                    <measurement group_id="O2" value="10.47" spread="4.479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment period: &quot;ON&quot; with non-TD, n=18, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="1.875"/>
                    <measurement group_id="O2" value="1.98" spread="2.987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment period: &quot;ON&quot; with TD, n=18, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="1.548"/>
                    <measurement group_id="O2" value="0.59" spread="1.985"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment period: &quot;OFF,&quot; n=18, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.57" spread="4.364"/>
                    <measurement group_id="O2" value="2.94" spread="2.954"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 of FU: &quot;ON,&quot; n=18, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.00" spread="3.309"/>
                    <measurement group_id="O2" value="12.13" spread="3.134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 of FU: &quot;ON&quot; without dyskinesia, n=18, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.17" spread="4.232"/>
                    <measurement group_id="O2" value="10.63" spread="3.948"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 of FU: &quot;ON&quot; with non-TD, n=18, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="1.933"/>
                    <measurement group_id="O2" value="1.50" spread="2.369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 of FU: &quot;ON&quot; with TD, n=18, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="2.083"/>
                    <measurement group_id="O2" value="0.52" spread="1.986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 of FU: &quot;OFF,&quot; n=18, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.83" spread="3.700"/>
                    <measurement group_id="O2" value="3.31" spread="2.642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 of FU: &quot;ON,&quot; n=16, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.34" spread="3.580"/>
                    <measurement group_id="O2" value="11.69" spread="3.562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 of FU: &quot;ON&quot; without dyskinesia, n=16, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.13" spread="4.138"/>
                    <measurement group_id="O2" value="9.98" spread="4.872"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 of FU: &quot;ON&quot; with non-TD, n=16, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.875"/>
                    <measurement group_id="O2" value="1.70" spread="2.838"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 of FU: &quot;ON&quot; with TD, n=16, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="1.500"/>
                    <measurement group_id="O2" value="0.80" spread="2.362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 of FU: &quot;OFF,&quot; n=16, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.47" spread="3.601"/>
                    <measurement group_id="O2" value="3.36" spread="2.857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>OFF: Treatment Period</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>-2.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.71</ci_lower_limit>
            <ci_upper_limit>-0.90</ci_upper_limit>
            <estimate_desc>OFF: Treatment Period: The AMs and differences (GSK962040 minus Placebo) were estimated using an analysis of covariance (ANCOVA) model fitting treatment and Baseline amount of hours spent ON/OFF as main effects.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ON: Treatment Period</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>1.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>3.48</ci_upper_limit>
            <estimate_desc>ON: Treatment Period: The AMs and differences (GSK962040 minus Placebo) were estimated using an analysis of covariance (ANCOVA) model fitting treatment and Baseline amount of hours spent ON/OFF as main effects.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Times a Participant Could Alternatively Tap Two Counter Keys 30 Centimeters Apart in 1 Minute (Min) at Baseline, Day1, Day 8, and Follow-up</title>
        <description>Participants were asked to alternatively tap two keys 30 centimeters apart in 1 minute in two trials with the most affected hand or the dominant hand in symmetric disease. The finger tapping was scored manually by the study staff. The finger-tapping assessment was repeated at eight separate time points (pre-dose, 0 min, 30 min, 60 min, 90 min, 120 min, 180 min, and 240 min post-dose) at each visit (Baseline, Day 1, and Day 8). At each time point, the mean of the two assessments was calculated.</description>
        <time_frame>Baseline, Day 1, and Day 8 at pre-dose and 0, 30, 60, 90, 120, 180, and 240 minutes post-dose; Follow-up visit (up to Day 25)</time_frame>
        <population>PD/Efficacy Population. Participants with available data (n=X, X in category titles) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 milligrams (mg) administered orally once daily for 7 to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Times a Participant Could Alternatively Tap Two Counter Keys 30 Centimeters Apart in 1 Minute (Min) at Baseline, Day1, Day 8, and Follow-up</title>
          <description>Participants were asked to alternatively tap two keys 30 centimeters apart in 1 minute in two trials with the most affected hand or the dominant hand in symmetric disease. The finger tapping was scored manually by the study staff. The finger-tapping assessment was repeated at eight separate time points (pre-dose, 0 min, 30 min, 60 min, 90 min, 120 min, 180 min, and 240 min post-dose) at each visit (Baseline, Day 1, and Day 8). At each time point, the mean of the two assessments was calculated.</description>
          <population>PD/Efficacy Population. Participants with available data (n=X, X in category titles) were analyzed.</population>
          <units>Finger taps per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: pre-dose, n=19, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.4" spread="47.53"/>
                    <measurement group_id="O2" value="77.8" spread="38.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 0 min, n=19, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.2" spread="49.84"/>
                    <measurement group_id="O2" value="80.1" spread="35.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 30 min, n=19, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.3" spread="42.91"/>
                    <measurement group_id="O2" value="85.2" spread="41.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 60 min, n=19, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.6" spread="42.32"/>
                    <measurement group_id="O2" value="89.3" spread="45.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 90 min, n=19, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.2" spread="44.14"/>
                    <measurement group_id="O2" value="90.8" spread="45.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 120 min, n=19, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.6" spread="40.99"/>
                    <measurement group_id="O2" value="92.0" spread="43.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 180 min, n=19, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.1" spread="47.19"/>
                    <measurement group_id="O2" value="92.8" spread="44.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 240 min, n=19, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.2" spread="44.60"/>
                    <measurement group_id="O2" value="93.2" spread="46.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: pre-dose, n=19, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3" spread="43.44"/>
                    <measurement group_id="O2" value="85.1" spread="40.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 0 min, n=19, 364</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.7" spread="40.78"/>
                    <measurement group_id="O2" value="86.8" spread="44.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 30 min, n=18, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.4" spread="43.95"/>
                    <measurement group_id="O2" value="92.4" spread="49.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 60 min, n=18, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.8" spread="44.80"/>
                    <measurement group_id="O2" value="94.6" spread="44.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 90 min, n=19, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" spread="50.46"/>
                    <measurement group_id="O2" value="91.4" spread="42.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 120 min, n=19, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.9" spread="50.51"/>
                    <measurement group_id="O2" value="96.4" spread="42.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 180 min, n=18, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0" spread="49.44"/>
                    <measurement group_id="O2" value="92.3" spread="41.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 240 min, n=18, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2" spread="51.97"/>
                    <measurement group_id="O2" value="97.6" spread="48.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: pre-dose, n=18, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7" spread="40.90"/>
                    <measurement group_id="O2" value="92.8" spread="43.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 0 min, n=18, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.0" spread="44.30"/>
                    <measurement group_id="O2" value="91.1" spread="42.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 30 min, n=18, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.8" spread="45.07"/>
                    <measurement group_id="O2" value="92.2" spread="41.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 60 min, n=18, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.6" spread="46.80"/>
                    <measurement group_id="O2" value="93.2" spread="39.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 90 min, n=18, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.0" spread="48.82"/>
                    <measurement group_id="O2" value="95.5" spread="42.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 120 min, n=18, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.2" spread="47.67"/>
                    <measurement group_id="O2" value="97.4" spread="42.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 180 min, n=18, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.8" spread="52.50"/>
                    <measurement group_id="O2" value="101.2" spread="49.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 240 min, n=18, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3" spread="53.30"/>
                    <measurement group_id="O2" value="102.8" spread="51.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up: n=18, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.4" spread="48.13"/>
                    <measurement group_id="O2" value="105.7" spread="56.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pre-dose: Day GSK962040 50 mg Vs Placebo Day 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>-2.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.79</ci_lower_limit>
            <ci_upper_limit>16.13</ci_upper_limit>
            <estimate_desc>Day 1, pre-dose: The AMs/differences (GSK962040 minus Placebo) were estimated using a MM fitting treatment, visit, time point (TP), treatment*visit*TP interaction, and BL score as fixed effects, TP as a repeated effect, and par. as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>0 min PD: GSK962040 50 mg Vs Placebo Day 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.39</ci_lower_limit>
            <ci_upper_limit>19.56</ci_upper_limit>
            <estimate_desc>Day 1, 0 min PD: The AMs/differences (GSK962040 minus Placebo) were estimated using a MM fitting treatment, visit, time point (TP), treatment*visit*TP interaction, and BL score as fixed effects, TP as a repeated effect, and par. as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1, 30 min PD</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>1.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.18</ci_lower_limit>
            <ci_upper_limit>20.86</ci_upper_limit>
            <estimate_desc>Day 1, 30 min PD: The AMs/differences (GSK962040 minus Placebo) were estimated using a MM fitting treatment, visit, time point (TP), treatment*visit*TP interaction, and BL score as fixed effects, TP as a repeated effect, and par. as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>60 min PD: GSK962040 50 mg Vs Placebo Day 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.72</ci_lower_limit>
            <ci_upper_limit>19.28</ci_upper_limit>
            <estimate_desc>Day 1, 60 min PD: The AMs/differences (GSK962040 minus Placebo) were estimated using a MM fitting treatment, visit, time point (TP), treatment*visit*TP interaction, and BL score as fixed effects, TP as a repeated effect, and par. as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>90 min PD: GSK962040 50 mg Vs Placebo Day 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>-3.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.35</ci_lower_limit>
            <ci_upper_limit>15.58</ci_upper_limit>
            <estimate_desc>Day 1, 90 min PD: The AMs/differences (GSK962040 minus Placebo) were estimated using a MM fitting treatment, visit, time point (TP), treatment*visit*TP interaction, and BL score as fixed effects, TP as a repeated effect, and par. as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>120 min PD: GSK962040 50 mg Vs Placebo Day 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>-4.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.13</ci_lower_limit>
            <ci_upper_limit>14.76</ci_upper_limit>
            <estimate_desc>Day 1, 120 min PD: The AMs/differences (GSK962040 minus Placebo) were estimated using a MM fitting treatment, visit, time point (TP), treatment*visit*TP interaction, and BL score as fixed effects, TP as a repeated effect, and par. as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>180 min PD: GSK962040 50 mg Vs Placebo Day 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>-6.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.36</ci_lower_limit>
            <ci_upper_limit>12.58</ci_upper_limit>
            <estimate_desc>Day 1, 180 min PD: The AMs/differences (GSK962040 minus Placebo) were estimated using a MM fitting treatment, visit, time point (TP), treatment*visit*TP interaction, and BL score as fixed effects, TP as a repeated effect, and par. as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>240 min PD: GSK962040 50 mg Vs Placebo Day 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.20</ci_lower_limit>
            <ci_upper_limit>19.75</ci_upper_limit>
            <estimate_desc>Day 1, 240 min PD: The AMs/differences (GSK962040 minus Placebo) were estimated using a MM fitting treatment, visit, time point (TP), treatment*visit*TP interaction, and BL score as fixed effects, TP as a repeated effect, and par. as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pre-dose: GSK962040 50 mg Vs Placebo Day 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>0.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.51</ci_lower_limit>
            <ci_upper_limit>19.52</ci_upper_limit>
            <estimate_desc>Day 8, pre-dose: The AMs/differences (GSK962040 minus Placebo) were estimated using a MM fitting treatment, visit, time point (TP), treatment*visit*TP interaction, and BL score as fixed effects, TP as a repeated effect, and par. as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>0 min PD: GSK962040 50 mg Vs Placebo Day 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>3.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.70</ci_lower_limit>
            <ci_upper_limit>22.33</ci_upper_limit>
            <estimate_desc>Day 8, 0 min PD: The AMs/differences (GSK962040 minus Placebo) were estimated using a MM fitting treatment, visit, time point (TP), treatment*visit*TP interaction, and BL score as fixed effects, TP as a repeated effect, and par. as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>30 min PD: GSK962040 50 mg Vs Placebo Day 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>-2.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.97</ci_lower_limit>
            <ci_upper_limit>16.08</ci_upper_limit>
            <estimate_desc>Day 8, 30 min PD: The AMs/differences (GSK962040 minus Placebo) were estimated using a MM fitting treatment, visit, time point (TP), treatment*visit*TP interaction, and BL score as fixed effects, TP as a repeated effect, and par. as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>60 min PD: GSK962040 50 mg Vs Placebo Day 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>-3.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.13</ci_lower_limit>
            <ci_upper_limit>15.88</ci_upper_limit>
            <estimate_desc>Day 8, 60 min PD: The AMs/differences (GSK962040 minus Placebo) were estimated using a MM fitting treatment, visit, time point (TP), treatment*visit*TP interaction, and BL score as fixed effects, TP as a repeated effect, and par. as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>90 min PD: GSK962040 50 mg Vs Placebo Day 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>-1.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.40</ci_lower_limit>
            <ci_upper_limit>17.63</ci_upper_limit>
            <estimate_desc>Day 8, 90 min PD: The AMs/differences (GSK962040 minus Placebo) were estimated using a MM fitting treatment, visit, time point (TP), treatment*visit*TP interaction, and BL score as fixed effects, TP as a repeated effect, and par. as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>120 min PD: GSK962040 50 mg Vs Placebo Day 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>-0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.70</ci_lower_limit>
            <ci_upper_limit>18.28</ci_upper_limit>
            <estimate_desc>Day 8, 120 min PD: The AMs/differences (GSK962040 minus Placebo) were estimated using a MM fitting treatment, visit, time point (TP), treatment*visit*TP interaction, and BL score as fixed effects, TP as a repeated effect, and par. as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>180 min PD: GSK962040 50 mg Vs Placebo Day 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>3.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.98</ci_lower_limit>
            <ci_upper_limit>22.02</ci_upper_limit>
            <estimate_desc>Day 8, 180 min PD: The AMs/differences (GSK962040 minus Placebo) were estimated using a MM fitting treatment, visit, time point (TP), treatment*visit*TP interaction, and BL score as fixed effects, TP as a repeated effect, and par. as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>240 min PD: GSK962040 50 mg Vs Placebo Day 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in AMs of change from BL</param_type>
            <param_value>4.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.91</ci_lower_limit>
            <ci_upper_limit>23.07</ci_upper_limit>
            <estimate_desc>Day 8, 240 min PD: The AMs/differences (GSK962040 minus Placebo) were estimated using a MM fitting treatment, visit, time point (TP), treatment*visit*TP interaction, and BL score as fixed effects, TP as a repeated effect, and par. as a random effect.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily L-DOPA Equivalent Dose at Baseline and on Days 1, 2, 3, 4, 5, 6, 7, 8, and 9</title>
        <description>Various formulations of L-DOPA were utilized by participants for the treatment of Parkinsonâ€™s Disease. The total daily L-DOPA equivalent dose was calculated as the sum of all L-DOPA equivalent doses for each L-DOPA-containing drug taken on the same day.</description>
        <time_frame>Baseline and Days 1, 2, 3, 4, 5, 6, 7, 8, and 9</time_frame>
        <population>PD/Efficacy Population. Participants with available data (n=X, X in category titles) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 milligrams (mg) administered orally once daily for 7 to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily L-DOPA Equivalent Dose at Baseline and on Days 1, 2, 3, 4, 5, 6, 7, 8, and 9</title>
          <description>Various formulations of L-DOPA were utilized by participants for the treatment of Parkinsonâ€™s Disease. The total daily L-DOPA equivalent dose was calculated as the sum of all L-DOPA equivalent doses for each L-DOPA-containing drug taken on the same day.</description>
          <population>PD/Efficacy Population. Participants with available data (n=X, X in category titles) were analyzed.</population>
          <units>Milligrams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, n=19, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.2" spread="41.14"/>
                    <measurement group_id="O2" value="164.5" spread="119.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, n=19, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="353.9" spread="174.85"/>
                    <measurement group_id="O2" value="368.6" spread="216.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, n=19, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="465.8" spread="229.61"/>
                    <measurement group_id="O2" value="514.5" spread="300.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, n=19, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="481.6" spread="243.79"/>
                    <measurement group_id="O2" value="516.9" spread="299.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4, n=19, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="481.6" spread="241.50"/>
                    <measurement group_id="O2" value="518.3" spread="313.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5, n=19, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="484.2" spread="243.13"/>
                    <measurement group_id="O2" value="503.0" spread="293.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6, n=17, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="516.2" spread="249.21"/>
                    <measurement group_id="O2" value="511.3" spread="307.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, n=17, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="486.8" spread="247.51"/>
                    <measurement group_id="O2" value="499.6" spread="310.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, n=17, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191.2" spread="175.43"/>
                    <measurement group_id="O2" value="281.3" spread="234.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9, n=0, 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.0"/>
                    <measurement group_id="O2" value="235.0" spread="121.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Day 1 and Day 8</title>
        <description>Blood pressure measurements were taken at pre-dose and at 0 min (completion of meal) on Day 1 and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
        <time_frame>Baseline, Day 1, and Day 8</time_frame>
        <population>All Subjects Population (ASP): all participants who received &gt;=1 dose of study medication. Participants with available data (n=X, X in category titles) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 milligrams (mg) administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 Total</title>
            <description>Participants received GSK962040 50 milligrams (mg) (except for one participant who received GSK962040 125 mg) administered orally once daily for 7 to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Day 1 and Day 8</title>
          <description>Blood pressure measurements were taken at pre-dose and at 0 min (completion of meal) on Day 1 and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
          <population>All Subjects Population (ASP): all participants who received &gt;=1 dose of study medication. Participants with available data (n=X, X in category titles) were analyzed.</population>
          <units>Millimeters of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP, Day 1: 0 min, n=19, 37, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="12.05"/>
                    <measurement group_id="O2" value="-2.5" spread="18.66"/>
                    <measurement group_id="O3" value="-2.1" spread="18.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 8: pre-dose, n=18, 36, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="13.24"/>
                    <measurement group_id="O2" value="-3.9" spread="13.19"/>
                    <measurement group_id="O3" value="-3.7" spread="13.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 8: 0 min, n=18, 36, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="11.55"/>
                    <measurement group_id="O2" value="-1.0" spread="15.04"/>
                    <measurement group_id="O3" value="-1.1" spread="14.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 1: 0 min, n=19, 37, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="7.67"/>
                    <measurement group_id="O2" value="-0.9" spread="7.51"/>
                    <measurement group_id="O3" value="-0.7" spread="7.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 8: pre-dose, n=18, 36, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="6.88"/>
                    <measurement group_id="O2" value="-0.9" spread="8.54"/>
                    <measurement group_id="O3" value="-0.8" spread="8.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 8: 0 min, n=18, 36, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="5.81"/>
                    <measurement group_id="O2" value="0.9" spread="8.32"/>
                    <measurement group_id="O3" value="0.9" spread="8.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Heart Rate at Day 1 and Day 8</title>
        <description>Heart rate measurements were taken at pre-dose and 0 min (completion of meal) on Day 1 and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
        <time_frame>Baseline, Day 1, and Day 8</time_frame>
        <population>ASP. Participants with available data (n=X, X in category titles) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 milligrams (mg) administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 Total</title>
            <description>Participants received GSK962040 50 milligrams (mg) (except for one participant who received GSK962040 125 mg) administered orally once daily for 7 to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Heart Rate at Day 1 and Day 8</title>
          <description>Heart rate measurements were taken at pre-dose and 0 min (completion of meal) on Day 1 and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
          <population>ASP. Participants with available data (n=X, X in category titles) were analyzed.</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1: 0 min, n=19, 37, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="7.30"/>
                    <measurement group_id="O2" value="0.8" spread="9.19"/>
                    <measurement group_id="O3" value="0.5" spread="9.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: pre-dose, n=18, 36, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="7.67"/>
                    <measurement group_id="O2" value="0.6" spread="6.12"/>
                    <measurement group_id="O3" value="0.0" spread="6.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 0 min, n=18, 36, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="7.64"/>
                    <measurement group_id="O2" value="-0.5" spread="6.80"/>
                    <measurement group_id="O3" value="-0.5" spread="6.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Indicated Electrocardiogram (ECG) Findings at Day 1 and Day 8</title>
        <description>ECG measurements were taken at pre-dose and 0 min (completion of meal) on Day 1 and Day 8. The Baseline value was the Day 1 pre-dose value. ECG findings were categorized as normal, abnormal - not clinically significant, and abnormal - clinically significant (CS), based on interpretation by the site.</description>
        <time_frame>Day 1 and Day 8</time_frame>
        <population>ASP. Participants with available data (n=X, X in category titles) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 milligrams (mg) administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 Total</title>
            <description>Participants received GSK962040 50 milligrams (mg) (except for one participant who received GSK962040 125 mg) administered orally once daily for 7 to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Indicated Electrocardiogram (ECG) Findings at Day 1 and Day 8</title>
          <description>ECG measurements were taken at pre-dose and 0 min (completion of meal) on Day 1 and Day 8. The Baseline value was the Day 1 pre-dose value. ECG findings were categorized as normal, abnormal - not clinically significant, and abnormal - clinically significant (CS), based on interpretation by the site.</description>
          <population>ASP. Participants with available data (n=X, X in category titles) were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1: pre-dose, Normal, n=19, 37, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: pre-dose, Abnormal - Not CS, n=19, 37, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: pre-dose, Abnormal - CS, n=19, 37, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 0 min, Normal, n=19, 37, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 0 min, Abnormal - Not CS, n=19, 37, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 0 min, Abnormal - CS, n=19, 37, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: pre-dose, Normal, n=18, 36, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: pre-dose, Abnormal - Not CS, n=18, 36, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: pre-dose, Abnormal - CS, n=18, 36, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 0 min, Normal, n=18, 36, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 0 min, Abnormal - Not CS, n=18, 36, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 0 min, Abnormal - CS, n=18, 36, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Albumin (ALB) and Total Protein (TP) at Day 4 and Day 8</title>
        <description>ALB and TP measurements were taken at pre-dose on Day 1 (Baseline), Day 4, and Day 8. Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
        <time_frame>Baseline, Day 4, and Day 8</time_frame>
        <population>ASP. Participants with available data (n=X, X in category titles) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 milligrams (mg) administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 Total</title>
            <description>Participants received GSK962040 50 milligrams (mg) (except for one participant who received GSK962040 125 mg) administered orally once daily for 7 to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Albumin (ALB) and Total Protein (TP) at Day 4 and Day 8</title>
          <description>ALB and TP measurements were taken at pre-dose on Day 1 (Baseline), Day 4, and Day 8. Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
          <population>ASP. Participants with available data (n=X, X in category titles) were analyzed.</population>
          <units>Grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALB, Day 4, n=18, 34, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="2.313"/>
                    <measurement group_id="O2" value="-0.38" spread="2.155"/>
                    <measurement group_id="O3" value="-0.37" spread="2.124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALB, Day 8, n=18, 34, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="2.220"/>
                    <measurement group_id="O2" value="-0.33" spread="2.084"/>
                    <measurement group_id="O3" value="-0.29" spread="2.065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TP, Day 4, n=18, 30, 31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="3.28"/>
                    <measurement group_id="O2" value="-0.9" spread="3.93"/>
                    <measurement group_id="O3" value="-1.0" spread="3.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TP, Day 8, n=15, 31, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0" spread="3.24"/>
                    <measurement group_id="O2" value="-0.3" spread="3.72"/>
                    <measurement group_id="O3" value="-0.3" spread="3.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Alkaline Phosphatase (ALP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), and Gamma Glutamyl Transferase (GGT) at Day 4 and Day 8</title>
        <description>ALP, ALT, AST, and GGT measurements were taken at pre-dose on Day 1 (Baseline), Day 4, and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
        <time_frame>Baseline, Day 4, and Day 8</time_frame>
        <population>ASP. Participants with available data (n=X, X in category titles) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 milligrams (mg) administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 Total</title>
            <description>Participants received GSK962040 50 milligrams (mg) (except for one participant who received GSK962040 125 mg) administered orally once daily for 7 to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alkaline Phosphatase (ALP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), and Gamma Glutamyl Transferase (GGT) at Day 4 and Day 8</title>
          <description>ALP, ALT, AST, and GGT measurements were taken at pre-dose on Day 1 (Baseline), Day 4, and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
          <population>ASP. Participants with available data (n=X, X in category titles) were analyzed.</population>
          <units>International units per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALP, Day 4, n=19, 33, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="5.26"/>
                    <measurement group_id="O2" value="2.4" spread="14.14"/>
                    <measurement group_id="O3" value="2.2" spread="13.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP, Day 8, n=18, 34, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="7.66"/>
                    <measurement group_id="O2" value="1.4" spread="13.35"/>
                    <measurement group_id="O3" value="1.2" spread="13.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Day 4, n=19, 33, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.4" spread="10.45"/>
                    <measurement group_id="O2" value="-5.9" spread="9.77"/>
                    <measurement group_id="O3" value="-7.1" spread="11.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Day 8, n=18, 34, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="6.88"/>
                    <measurement group_id="O2" value="-0.4" spread="5.46"/>
                    <measurement group_id="O3" value="-0.6" spread="5.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Day 4, n=19, 32, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="3.16"/>
                    <measurement group_id="O2" value="-1.2" spread="2.89"/>
                    <measurement group_id="O3" value="-1.3" spread="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Day 8, n=16, 31, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="4.55"/>
                    <measurement group_id="O2" value="1.0" spread="3.65"/>
                    <measurement group_id="O3" value="0.9" spread="3.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, Day 4, n=19, 33, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="3.20"/>
                    <measurement group_id="O2" value="-0.8" spread="3.06"/>
                    <measurement group_id="O3" value="-0.9" spread="3.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, Day 4, n=18, 33, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="5.22"/>
                    <measurement group_id="O2" value="-1.0" spread="5.02"/>
                    <measurement group_id="O3" value="-1.0" spread="4.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Calcium, Chloride, Carbon Dioxide Content (CO2)/Bicarbonate (BC), Glucose, Potassium, Sodium, Urea/Blood Urea Nitrogen (BUN), and Uric Acid (UA) at Day 4 and Day 8</title>
        <description>Calcium, chloride, CO2/BC, glucose, potassium, sodium, urea/BUN, and UA measurements were taken at pre-dose on Day 1 (Baseline), Day 4, and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
        <time_frame>Baseline, Day 4, and Day 8</time_frame>
        <population>ASP. Participants with available data (n=X, X in category titles) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 milligrams (mg) administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 Total</title>
            <description>Participants received GSK962040 50 milligrams (mg) (except for one participant who received GSK962040 125 mg) administered orally once daily for 7 to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Calcium, Chloride, Carbon Dioxide Content (CO2)/Bicarbonate (BC), Glucose, Potassium, Sodium, Urea/Blood Urea Nitrogen (BUN), and Uric Acid (UA) at Day 4 and Day 8</title>
          <description>Calcium, chloride, CO2/BC, glucose, potassium, sodium, urea/BUN, and UA measurements were taken at pre-dose on Day 1 (Baseline), Day 4, and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
          <population>ASP. Participants with available data (n=X, X in category titles) were analyzed.</population>
          <units>Millimoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Calcium, Day 4, n=19, 34, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.010" spread="0.0746"/>
                    <measurement group_id="O2" value="-0.009" spread="0.0659"/>
                    <measurement group_id="O3" value="-0.011" spread="0.0667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, Day 8, n=18, 35, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.026" spread="0.0756"/>
                    <measurement group_id="O2" value="-0.018" spread="0.0662"/>
                    <measurement group_id="O3" value="-0.017" spread="0.0652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, Day 4, n=19, 33, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.37" spread="1.832"/>
                    <measurement group_id="O2" value="-0.42" spread="2.346"/>
                    <measurement group_id="O3" value="-0.41" spread="2.311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, Day 8, n=18, 33, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="2.570"/>
                    <measurement group_id="O2" value="0.52" spread="1.734"/>
                    <measurement group_id="O3" value="0.53" spread="1.710"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CO2/BC, Day 4, n=9, 21, 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="2.833"/>
                    <measurement group_id="O2" value="0.16" spread="2.602"/>
                    <measurement group_id="O3" value="0.20" spread="2.546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CO2/BC, Day 8, n=8, 22, 23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="2.053"/>
                    <measurement group_id="O2" value="0.23" spread="2.139"/>
                    <measurement group_id="O3" value="0.13" spread="2.141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, Day 4, n=19, 35, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" spread="2.944"/>
                    <measurement group_id="O2" value="0.14" spread="1.198"/>
                    <measurement group_id="O3" value="0.15" spread="1.185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, Day 8, n=18, 36, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.865"/>
                    <measurement group_id="O2" value="0.09" spread="0.594"/>
                    <measurement group_id="O3" value="-0.09" spread="0.594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, Day 4, n=19, 32, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.008" spread="0.3393"/>
                    <measurement group_id="O2" value="0.168" spread="0.3408"/>
                    <measurement group_id="O3" value="0.151" spread="0.3497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, Day 8, n=16, 31, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.055" spread="0.3405"/>
                    <measurement group_id="O2" value="0.048" spread="0.2897"/>
                    <measurement group_id="O3" value="0.043" spread="0.2862"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, Day 4, n=19, 34, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.89" spread="2.787"/>
                    <measurement group_id="O2" value="-0.56" spread="1.779"/>
                    <measurement group_id="O3" value="-0.51" spread="1.772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, Day 8, n=18, 34, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread="3.202"/>
                    <measurement group_id="O2" value="0.21" spread="1.647"/>
                    <measurement group_id="O3" value="0.29" spread="1.690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN, Day 4, n=17, 32, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="1.757"/>
                    <measurement group_id="O2" value="0.00" spread="1.496"/>
                    <measurement group_id="O3" value="-0.02" spread="1.477"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN, Day 8, n=17, 34, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="1.318"/>
                    <measurement group_id="O2" value="0.13" spread="1.308"/>
                    <measurement group_id="O3" value="0.14" spread="1.289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UA, Day 4, n=16, 30, 31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.22" spread="23.416"/>
                    <measurement group_id="O2" value="0.53" spread="29.735"/>
                    <measurement group_id="O3" value="-0.78" spread="30.127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UA, Day 8, n=14, 29, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.56" spread="22.601"/>
                    <measurement group_id="O2" value="6.39" spread="30.819"/>
                    <measurement group_id="O3" value="6.17" spread="30.306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Absolute Neutrophil Count (ANC), and Platelet Count (PC) at Day 4 and Day 8</title>
        <description>Basophils, eosinophils, lymphocytes, monocytes, total ANC, and PC measurements were taken at pre-dose on Day 1 (Baseline), Day 4, and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
        <time_frame>Baseline, Day 4, and Day 8</time_frame>
        <population>ASP. Participants with available data (n=X, X in category titles) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 milligrams (mg) administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 Total</title>
            <description>Participants received GSK962040 50 milligrams (mg) (except for one participant who received GSK962040 125 mg) administered orally once daily for 7 to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Absolute Neutrophil Count (ANC), and Platelet Count (PC) at Day 4 and Day 8</title>
          <description>Basophils, eosinophils, lymphocytes, monocytes, total ANC, and PC measurements were taken at pre-dose on Day 1 (Baseline), Day 4, and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
          <population>ASP. Participants with available data (n=X, X in category titles) were analyzed.</population>
          <units>Giga (10^9) cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophils, Day 4, n=19, 34, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.003" spread="0.0200"/>
                    <measurement group_id="O2" value="-0.006" spread="0.0247"/>
                    <measurement group_id="O3" value="-0.006" spread="0.0244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils, Day 8, n=17, 35, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.006" spread="0.0153"/>
                    <measurement group_id="O2" value="-0.001" spread="0.0195"/>
                    <measurement group_id="O3" value="-0.001" spread="0.0192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, Day 4, n=19, 34, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003" spread="0.1219"/>
                    <measurement group_id="O2" value="-0.031" spread="0.0584"/>
                    <measurement group_id="O3" value="-0.034" spread="0.0599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, Day 8, n=17, 35, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.016" spread="0.0519"/>
                    <measurement group_id="O2" value="-0.001" spread="0.0466"/>
                    <measurement group_id="O3" value="0.000" spread="0.0467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, Day 4, n=19, 34, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.093" spread="0.4326"/>
                    <measurement group_id="O2" value="0.044" spread="0.3592"/>
                    <measurement group_id="O3" value="0.033" spread="0.3592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, Day 8, n=17, 35, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.049" spread="0.3258"/>
                    <measurement group_id="O2" value="0.076" spread="0.5874"/>
                    <measurement group_id="O3" value="0.073" spread="0.5793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, Day 4, n=19, 34, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.006" spread="0.1313"/>
                    <measurement group_id="O2" value="0.002" spread="0.0923"/>
                    <measurement group_id="O3" value="0.004" spread="0.0913"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, Day 8, n=17, 35, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.004" spread="0.0860"/>
                    <measurement group_id="O2" value="-0.013" spread="0.0928"/>
                    <measurement group_id="O3" value="-0.013" spread="0.0916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total ANC , Day 4, n=19, 34, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.021" spread="0.8866"/>
                    <measurement group_id="O2" value="0.392" spread="0.9480"/>
                    <measurement group_id="O3" value="0.406" spread="0.9377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total ANC , Day 8, n=17, 35, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.007" spread="0.8586"/>
                    <measurement group_id="O2" value="-0.114" spread="0.8500"/>
                    <measurement group_id="O3" value="-0.122" spread="0.8392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC, Day 4, n=19, 34, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="18.45"/>
                    <measurement group_id="O2" value="3.6" spread="18.76"/>
                    <measurement group_id="O3" value="3.3" spread="18.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC, Day 8, n=17, 35, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="24.42"/>
                    <measurement group_id="O2" value="1.4" spread="22.97"/>
                    <measurement group_id="O3" value="0.7" spread="22.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) at Day 4 and Day 8</title>
        <description>Hemoglobin and MCHC measurements were taken at pre-dose on Day 1 (Baseline), Day 4, and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
        <time_frame>Baseline, Day 4, and Day 8</time_frame>
        <population>ASP. Participants with available data (n=X, X in category titles) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 milligrams (mg) administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 Total</title>
            <description>Participants received GSK962040 50 milligrams (mg) (except for one participant who received GSK962040 125 mg) administered orally once daily for 7 to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) at Day 4 and Day 8</title>
          <description>Hemoglobin and MCHC measurements were taken at pre-dose on Day 1 (Baseline), Day 4, and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
          <population>ASP. Participants with available data (n=X, X in category titles) were analyzed.</population>
          <units>Grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin, Day 4, n=19, 34, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="6.53"/>
                    <measurement group_id="O2" value="-2.0" spread="6.35"/>
                    <measurement group_id="O3" value="-2.3" spread="6.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, Day 8, n=17, 35, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="4.27"/>
                    <measurement group_id="O2" value="-2.3" spread="4.71"/>
                    <measurement group_id="O3" value="-2.2" spread="4.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC, Day 4, n=13, 24, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0" spread="8.85"/>
                    <measurement group_id="O2" value="0.6" spread="8.83"/>
                    <measurement group_id="O3" value="0.6" spread="8.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC, Day 8, n=12, 25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="8.30"/>
                    <measurement group_id="O2" value="-2.3" spread="8.47"/>
                    <measurement group_id="O3" value="-2.3" spread="8.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematocrit at Day 4 and Day 8</title>
        <description>Hematocrit measurements were taken at pre-dose on Day 1 (Baseline), Day 4, and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
        <time_frame>Baseline, Day 4, and Day 8</time_frame>
        <population>ASP. Participants with available data (n=X, X in category titles) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 milligrams (mg) administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 Total</title>
            <description>Participants received GSK962040 50 milligrams (mg) (except for one participant who received GSK962040 125 mg) administered orally once daily for 7 to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematocrit at Day 4 and Day 8</title>
          <description>Hematocrit measurements were taken at pre-dose on Day 1 (Baseline), Day 4, and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
          <population>ASP. Participants with available data (n=X, X in category titles) were analyzed.</population>
          <units>proportion of 1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 4, n=19, 34, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0059" spread="0.02331"/>
                    <measurement group_id="O2" value="-0.0059" spread="0.02029"/>
                    <measurement group_id="O3" value="-0.0067" spread="0.02051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, n=17, 35, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0044" spread="0.01383"/>
                    <measurement group_id="O2" value="-0.0037" spread="0.01702"/>
                    <measurement group_id="O3" value="-0.0039" spread="0.01682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Corpuscle Hemoglobin (MCH) at Day 4 and Day 8</title>
        <description>MCH measurements were taken at pre-dose on Day 1 (Baseline), Day 4, and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
        <time_frame>Baseline, Day 4, and Day 8</time_frame>
        <population>ASP. Participants with available data (n=X, X in category titles) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 milligrams (mg) administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 Total</title>
            <description>Participants received GSK962040 50 milligrams (mg) (except for one participant who received GSK962040 125 mg) administered orally once daily for 7 to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Corpuscle Hemoglobin (MCH) at Day 4 and Day 8</title>
          <description>MCH measurements were taken at pre-dose on Day 1 (Baseline), Day 4, and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
          <population>ASP. Participants with available data (n=X, X in category titles) were analyzed.</population>
          <units>Picograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 4, n=19, 34, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.464"/>
                    <measurement group_id="O2" value="-0.06" spread="0.744"/>
                    <measurement group_id="O3" value="0.07" spread="0.737"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, n=17, 35, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.718"/>
                    <measurement group_id="O2" value="-0.20" spread="0.832"/>
                    <measurement group_id="O3" value="0.19" spread="0.826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Corpuscle Volume (MCV) at Day 4 and Day 8</title>
        <description>MCV measurements were taken at pre-dose on Day 1 (Baseline), Day 4, and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
        <time_frame>Baseline, Day 4, and Day 8</time_frame>
        <population>ASP. Participants with available data (n=X, X in category titles) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 milligrams (mg) administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 Total</title>
            <description>Participants received GSK962040 50 milligrams (mg) (except for one participant who received GSK962040 125 mg) administered orally once daily for 7 to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Corpuscle Volume (MCV) at Day 4 and Day 8</title>
          <description>MCV measurements were taken at pre-dose on Day 1 (Baseline), Day 4, and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
          <population>ASP. Participants with available data (n=X, X in category titles) were analyzed.</population>
          <units>Femtoliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 4, n=19, 34, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="1.945"/>
                    <measurement group_id="O2" value="-0.14" spread="1.339"/>
                    <measurement group_id="O3" value="-0.17" spread="1.334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, n=17, 35, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" spread="1.322"/>
                    <measurement group_id="O2" value="-0.05" spread="1.401"/>
                    <measurement group_id="O3" value="-0.06" spread="1.381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Red Blood Cell Count (RBC) and White Blood Cell Count (WBC) at Day 4 and Day 8</title>
        <description>RBC and WBC measurements were taken at pre-dose on Day 1 (Baseline), Day 4, and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
        <time_frame>Baseline, Day 4, and Day 8</time_frame>
        <population>ASP. Participants with available data (n=X, X in category titles) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 milligrams (mg) administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 Total</title>
            <description>Participants received GSK962040 50 milligrams (mg) (except for one participant who received GSK962040 125 mg) administered orally once daily for 7 to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Red Blood Cell Count (RBC) and White Blood Cell Count (WBC) at Day 4 and Day 8</title>
          <description>RBC and WBC measurements were taken at pre-dose on Day 1 (Baseline), Day 4, and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
          <population>ASP. Participants with available data (n=X, X in category titles) were analyzed.</population>
          <units>Giga (10^9) cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RBC, Day 4, n=19, 34, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.055" spread="0.2345"/>
                    <measurement group_id="O2" value="0.068" spread="0.2138"/>
                    <measurement group_id="O3" value="-0.074" spread="0.2140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, Day 8, n=17, 35, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.073" spread="0.1270"/>
                    <measurement group_id="O2" value="0.041" spread="0.1752"/>
                    <measurement group_id="O3" value="-0.043" spread="0.1730"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, Day 4, n=19, 34, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.140" spread="0.9284"/>
                    <measurement group_id="O2" value="0.390" spread="1.0592"/>
                    <measurement group_id="O3" value="0.392" spread="1.0437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, Day 8, n=17, 35, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.036" spread="0.8961"/>
                    <measurement group_id="O2" value="-0.154" spread="0.9006"/>
                    <measurement group_id="O3" value="-0.161" spread="0.8886"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Reticulocytes (RET) at Day 4 and Day 8</title>
        <description>RET measurements were taken at pre-dose on Day 1 (Baseline), Day 4, and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
        <time_frame>Baseline, Day 4, and Day 8</time_frame>
        <population>ASP. Participants with available data (n=X, X in category titles) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 milligrams (mg) administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 Total</title>
            <description>Participants received GSK962040 50 milligrams (mg) (except for one participant who received GSK962040 125 mg) administered orally once daily for 7 to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Reticulocytes (RET) at Day 4 and Day 8</title>
          <description>RET measurements were taken at pre-dose on Day 1 (Baseline), Day 4, and Day 8. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
          <population>ASP. Participants with available data (n=X, X in category titles) were analyzed.</population>
          <units>Tera (10^12) cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RET, Day 4, n=16, 28, 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0075"/>
                    <measurement group_id="O2" value="0.002" spread="0.0093"/>
                    <measurement group_id="O3" value="0.001" spread="0.0098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RET, Day 8, n=13, 28, 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" spread="0.0080"/>
                    <measurement group_id="O2" value="0.001" spread="0.0093"/>
                    <measurement group_id="O3" value="0.001" spread="0.0095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)</title>
        <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, is a congenital anomaly or birth defect, is associated with liver injury and impaired liver function, or are serious events as per the medical or scientific judgment.</description>
        <time_frame>From the start of study medication until Follow-up (up to Day 25)</time_frame>
        <population>All Subjects Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 milligrams (mg) administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 Total</title>
            <description>Participants received GSK962040 50 milligrams (mg) (except for one participant who received GSK962040 125 mg) administered orally once daily for 7 to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)</title>
          <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, is a congenital anomaly or birth defect, is associated with liver injury and impaired liver function, or are serious events as per the medical or scientific judgment.</description>
          <population>All Subjects Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GSK962040 Area Under the Plasma Concentration-time Curve From Zero to 5.5 Hours (AUC[0-5.5] and Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC[0-inf]) at Days 1 and 8</title>
        <description>GSK AUC(0-5.5) and AUC(0-inf) were derived from GSK962040 plasma concentration-time data. Only participants who received GSK962040 50 mg were analyzed. AUC is a measure of levodopa exposure. Data for AUC(0-inf) was analyzed and was only available for Day 1 and not for Day 8.</description>
        <time_frame>Day 1 and Day 8</time_frame>
        <population>PD/Efficacy Population. Participants with available data (n=X, X in category titles) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 milligrams (mg) administered orally once daily for 7 to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>GSK962040 Area Under the Plasma Concentration-time Curve From Zero to 5.5 Hours (AUC[0-5.5] and Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC[0-inf]) at Days 1 and 8</title>
          <description>GSK AUC(0-5.5) and AUC(0-inf) were derived from GSK962040 plasma concentration-time data. Only participants who received GSK962040 50 mg were analyzed. AUC is a measure of levodopa exposure. Data for AUC(0-inf) was analyzed and was only available for Day 1 and not for Day 8.</description>
          <population>PD/Efficacy Population. Participants with available data (n=X, X in category titles) were analyzed.</population>
          <units>Nanograms.hour/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-5.5): Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1632.5" spread="38.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-5.5): Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="3036.9" spread="45.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-inf): Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2972.8" spread="49.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GSK962040 Percentage of AUC(0-inf) Obtained by Extrapolation (%AUCex) at Day 1</title>
        <description>GSK962040 %AUCex was derived from GSK962040 plasma concentration-time data. %AUCex is the percentage of the AUC(0-inf) extrapolated from the last PK sample drawn to infinity. This parameter is only reported in conjunction with single-dose AUC(0-inf). Only participants who received GSK962040 50 mg were analyzed. AUC is a measure of levodopa exposure.</description>
        <time_frame>Day 1</time_frame>
        <population>PD/Efficacy Population. Participants with available data (n=X, X in category titles) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 milligrams (mg) administered orally once daily for 7 to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>GSK962040 Percentage of AUC(0-inf) Obtained by Extrapolation (%AUCex) at Day 1</title>
          <description>GSK962040 %AUCex was derived from GSK962040 plasma concentration-time data. %AUCex is the percentage of the AUC(0-inf) extrapolated from the last PK sample drawn to infinity. This parameter is only reported in conjunction with single-dose AUC(0-inf). Only participants who received GSK962040 50 mg were analyzed. AUC is a measure of levodopa exposure.</description>
          <population>PD/Efficacy Population. Participants with available data (n=X, X in category titles) were analyzed.</population>
          <units>Percentage</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="41.64" spread="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GSK962040 Cmax at Day1 and Day 8</title>
        <description>GSK962040 Cmax was derived from GSK962040 plasma concentration-time data. Only participants who received GSK962040 50 mg were analyzed.</description>
        <time_frame>Day 1 and Day 8</time_frame>
        <population>PD/Efficacy Population. Participants with available data (n=X, X in category titles) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 milligrams (mg) administered orally once daily for 7 to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>GSK962040 Cmax at Day1 and Day 8</title>
          <description>GSK962040 Cmax was derived from GSK962040 plasma concentration-time data. Only participants who received GSK962040 50 mg were analyzed.</description>
          <population>PD/Efficacy Population. Participants with available data (n=X, X in category titles) were analyzed.</population>
          <units>Nanograms/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="501.0" spread="45.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="788.3" spread="46.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GSK962040 Tmax at Day1 and Day 8</title>
        <description>GSK962040 tmax was derived from GSK962040 plasma concentration-time data. Only participants who received GSK962040 50 mg were analyzed.</description>
        <time_frame>Day 1 and Day 8</time_frame>
        <population>PD/Efficacy Population. Participants with available data (n=X, X in category titles) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 milligrams (mg) administered orally once daily for 7 to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>GSK962040 Tmax at Day1 and Day 8</title>
          <description>GSK962040 tmax was derived from GSK962040 plasma concentration-time data. Only participants who received GSK962040 50 mg were analyzed.</description>
          <population>PD/Efficacy Population. Participants with available data (n=X, X in category titles) were analyzed.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.750" lower_limit="0.25" upper_limit="3.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.000" lower_limit="0.25" upper_limit="3.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Post-randomization adverse events include those that occured on or after the randomization date.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received placebo administered orally once daily for 7 to 9 days.</description>
        </group>
        <group group_id="E2">
          <title>GSK962040 50 mg</title>
          <description>Participants received GSK962040 50 milligrams (mg) administered orally once daily for 7 to 9 days.</description>
        </group>
        <group group_id="E3">
          <title>GSK962040 125 mg</title>
          <description>Participants received GSK962040 125 milligrams (mg) administered orally once daily for 7 to 9 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Parkinsonâ€™s disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Metamorphopsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Clumsiness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Micturition disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

